Infliximab Antibody | AbD19370_hIgG1

//www.bio-rad-antibodies.com/infliximab-antibody-abd19370-higg1-hca215.html?RenderPageSpecific=1
Infliximab Antibody | AbD19370_hIgG1 gallery image 1

HCA215 Specificity ELISA

To confirm antibody specificity, a microtiter plate was coated overnight with various antigens at a concentration of 5µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated HCA215 at 2µg/ml, followed by QuantaBlu fluorogenic peroxidase substrate

Enlarge
Infliximab Antibody | AbD19370_hIgG1 gallery image 2

Infliximab bound to TNF-α still binds to HCA215

A microtiter plate was coated overnight with HCA215 (as Fab fragment) at 5.0 µg/mL. After washing and blocking with PBST+5% BSA, Infliximab alone (red circles), or with 5.0 fold molar excess of TNF-α (black squares) was added in the given concentrations. Free or TNF-α bound Infliximab binding to HCA215 was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P)

Enlarge
Infliximab Antibody | AbD19370_hIgG1 gallery image 3

Infliximab Bridging ELISA for Pharmacokinetic (PK) Assay Development

A microtiter plate was coated overnight with HCA212 at a concentration of 5µg/ml. After washing and blocking with PBST+5% BSA, Infliximab spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated HCA215 at 2µg/ml in HISPEC assay diluent (BUF049), and QuantaBlu fluorogenic peroxidase substrate

Enlarge
Infliximab Antibody | AbD19370_hIgG1 gallery image 4

HCA215 Bridging ELISA for Anti-Drug Antibody (ADA) Assay Development

A microtiter plate was coated overnight with Infliximab at a concentration of 1µg/ml. After washing and blocking with PBST+5% BSA, anti Infliximab HCA215 spiked in 10% human serum was added at the given concentrations. Detection was performed using HRP-conjugated Infliximab

Enlarge
  • Infliximab Antibody | AbD19370_hIgG1 thumbnail image 1
  • Infliximab Antibody | AbD19370_hIgG1 thumbnail image 2
  • Infliximab Antibody | AbD19370_hIgG1 thumbnail image 3
  • Infliximab Antibody | AbD19370_hIgG1 thumbnail image 4
  • Human anti Infliximab
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-infliximab antibody is a non-neutralizing anti-idiotypic antibody in IgG1 format, suitable for bioanalytical assays for infliximab or biosimilars. It does not inhibit the binding of infliximab to TNF alpha; it is ideal for PK bridging ELISA to measure total drug and as calibrator in ADA assay.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD19370_hIgG1
    • Isotype
      IgG1
    1 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA215Edatasheet pdfdatasheet pdf0.1 mg
      HCA215
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti Infliximab, clone AbD19370_hIgG1, is an anti-idiotypic antibody that specifically recognizes free infliximab monoclonal antibody and infliximab when bound to its target, Tumor Necrosis Factor Alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products in patient samples.

        Clone AbD19370_hIgG1 is not paratope-specific and is non-inhibitory; it binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab, but not rituximab. The antibody can be used as a detection antibody in a pharmacokinetic (PK) assay in the bridging format to measure total drug (free, partially bound and fully bound). As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

        Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It is directed against TNFα and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.

        View a summary of all anti-infliximab antibodies.
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
      • Immunogen
        Infliximab
      • Purity
      • Affinity
        The monovalent intrinsic affinity of this antibody was measured as KD=1.4 nM by real time, label-free molecular interaction analysis on immobilized infliximab.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml.
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline.
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
      • Shelf Life
        12 months from date of despatch.
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, a wholly owned subsidiary of Bio-Rad Laboratories Inc., Zeppelinstr. 4, 82178 Puchheim, Germany.
        Remicade is a registered trademark of Janssen Biotech Inc.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • ELISA
        This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 as the capture reagent.
        Protocol: PK bridging ELISA to measure total drug
        Protocol: ADA bridging ELISA
      • Immunohistology
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Western Blotting
      • Instructions For Use

      Additional Infliximab Antibody Formats

      Formats Clone Applications Sizes available
      Infliximab Antibody : Purified AbD19370_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            Mouse anti Human IgG (Fc) CH2 Domain:HRPMCA647P0.2 mgC *, E
            MCA647P
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            Human anti InfliximabHCA2120.1 mgE
            HCA212
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A
            Recombinant Human TNF AlphaPHP05150 µgE, FN, WB
            PHP051

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...